摘要
糖皮质激素地塞米松是临床广泛应用的一类免疫抑制剂。近年来研究发现,在免疫应答反应的早期,地塞米松是通过影响体内的树突状细胞(dendritic cell,DC)而发挥作用的。地塞米松可通过抑制DC的分化和成熟、改变DC的表型和DC的某些重要生物学功能,抑制特异性免疫应答反应的启动并减少炎性细胞因子的产生。利用地塞米松对DC的影响来治疗自身免疫病、肿瘤、移植排斥反应等疾病可能会成为基础和临床医学研究的新热点。
Dexamethasone belongs to Glucocorticoids and is one kind of widely used immunosuppressire agents in clinical practice. Recent researches have found that in the early stage of immue responses, Dexamethasone works by affecting dendritic cells in vivo. Dexamethasone can restrain specific immune response priming and reduce inflammatory factor releasing by inhibiting differentiation and maturation of dendritic cells, changing phenotype and some important biologicall functions of dendritic cells. It has become a new focus in basic and clinical medicine to apply Dexamethasone in treatment of autoimmune diseases, tumor, graft rejection reaction and other diseases through its influence on dendritic cells.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2009年第1期113-116,共4页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
北京市教委科技发展计划资助项目(KM200710025005)
关键词
地塞米松
树突状细胞
免疫耐受
Dexamethasone
dendritic cell
im- mune tolerance
